Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc (BDRX): ~5 mo cash runway. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
5.2 months
D/E 0.59 · 0% dilution
N/A
N/A
N/A
N/A
A transparent, data-derived signal for Biodexa Pharmaceuticals Plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.3M
Cash
$8.5M
Quarterly Burn
$5.6M
Runway
5.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Frequently asked questions
What is Biodexa Pharmaceuticals Plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Biodexa Pharmaceuticals Plc has approximately 5.2 months of cash runway.
What is Biodexa Pharmaceuticals Plc's market capitalization?
Biodexa Pharmaceuticals Plc's market capitalization is approximately $2.3M.
Who is the CEO of Biodexa Pharmaceuticals Plc?
Mr. Stephen Anthony Stamp is the chief executive officer of Biodexa Pharmaceuticals Plc (BDRX).
Get the full picture on Biodexa Pharmaceuticals Plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.